Perioperative Management of Patients on Chronic Aspirin Therapy for Elective Brain Surgery: A Delphi Study
This Delphi study provides experience-based recommendations for managing chronic aspirin therapy in neurosurgical patients. The panel strongly supports aspirin continuation in high-thrombotic-risk patients, with cessation 5 to 7 days before high-bleeding-risk surgeries. Individualized management is advised for low-bleeding-risk procedures and low-thrombotic-risk patients. Future research should further clarify aspirin management in these groups and explore the role of platelet function testing in neurosurgical settings.
Authors
- Alexander Kulikov (ORCID: https://orcid.org/0000-0002-2852-6544)
- Federico Bilotta (ORCID: https://orcid.org/0000-0003-2496-6646)
- Philip M. Jones (ORCID: https://orcid.org/0000-0003-2296-6327)
- Ilana I. Logvinov (ORCID: https://orcid.org/0000-0002-8393-1817)
- Shaun E. Gruenbaum (ORCID: https://orcid.org/0000-0002-3214-6448)
- Ivana Erac
Institutions
- Burdenko Neurosurgery Institute (RU)
- Mayo Clinic in Florida (US)
- Austin Health (AU)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Journal of Neurosurgical Anesthesiology
- Published
- 2025-04-30
- DOI
- https://doi.org/10.1097/ana.0000000000001036
- Primary Topic
- Cardiac, Anesthesia and Surgical Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00